Search results for: Real World Evidence (RWE)
Filter search results
The R&D Cost of a New Medicine
1 December 2012
The cost of R&D for a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of intellectual curiosity or…
Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
17 January 2024
With healthcare systems responsible for 4%-5% of global greenhouse gas emissions (Watts et al., 2017), it is imperative that we scrutinise the environmental impact of the pharmaceutical industry, acknowledging its…
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
1 October 2010
Antimicrobial resistance (AMR) to drugs, a natural and unavoidable consequence of treating infectious diseases, is a growing global public health threat. The EU Commission is to develop comprehensive proposals by…
Enhancing the Benefits from Biomedical and Health Research Spillovers
1 October 2010
Research spillovers may exist when research by one organisation creates increased output for other organisations that operate in the same or another sector of the economy. Both the mechanisms and…
Innovation in Medicines: Can We Value Progress?
1 August 2010
Summarised in this publication are the main points and conclusions from a discussion facilitated by OHE that focused on innovation in the pharmaceutical industry. Participants included representatives of the pharmaceutical…
Forward Together: Complementarity of Public and Charitable Research with Respect to Private Research Spending
9 January 2009
The debate continues as to whether public/charitable research replaces private research that otherwise would have occurred, or stimulates additional private research, or does neither. Given the extent of public and…
Medical Research: What’s It Worth?
1 November 2008
Understanding the nature, extent and processes involved in the return on investment in medical research has been largely neglected as an area of serious scientific study. This report is the…
Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions
1 December 2006
Objective To model the cost-effectiveness for donors of investing in R&D projects into global diseases via public private partnerships for product development (PD PPPs). Methods We modelled the R&D process…
Risk and Return in the Pharmaceutical Industry
1 August 1999
This book has been built up from the papers delivered at the Office of Health Economics conference which took place at the Langham Hilton Hotel, London, on 5 December 1996….